IL6 and COVID-19: Anti‐inflammatory compounds currently used in the management of COVID‐19, for example, inhibit IL‐6 signalling (tocilizumab), interfere with JAK‐STAT signalling (baricitinib or tofacitinib), or inhibit the IL‐1 signalling pathway (anakinra).8